3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Hormone-receptor-positive Breast Cancer
1
Desmoid Tumors
1
Breast Cancer Patients in Premenopausal
1
Breast Cancer Organoids
1
Interventions
Carboplatin
15
camrelizumab
11
Capecitabine
11
130-nm albumin-bound paclitaxel
10
pembrolizumab
8
eribulin
8
Paclitaxel
8
Cyclophosphamide
8
Epirubicin
7
Gemcitabine
6
Cisplatin
6
tislelizumab
5
apatinib
5
atezolizumab
4
anlotinib
4
Taxes
4
Nivolumab
4
Docetaxel
4
Bevacizumab
4
toripalimab
3
Vinorelbine
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Doxorubicin
3
Albumin-Bound Paclitaxel
3
talazoparib
2
spartalizumab
2
olaparib
2
fluzoparib
2
famitinib
2
Zoledronic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Triple Negative Breast Neoplasms
×
Toremifene
×
Clear all
NCT02089854
2016-12-02
AETNBC
Peking Union Medical College Hospital
Phase 4
Unknown
800 enrolled